Literature DB >> 2671477

[Effect of captopril therapy on sodium and water excretion in patients with liver cirrhosis and ascites].

R Brunkhorst1, E Wrenger, K Kühn, F W Schmidt, K Koch.   

Abstract

UNLABELLED: Ascites in patients with cirrhosis of the liver frequently is refractory to diuretic treatment. It was postulated that vasoconstriction of the renal cortex, mediated by activation of the renin-angiotensin-aldosterone-system (RAAS), may be one course of the disturbed sodium- and water-excretion in these patients. We therefore investigated in 14 cirrhotic patients with ascites under constant diuretic treatment the effects of low-dose captopril therapy on urinary sodium- and potassium-excretion, body weight, abdominal girth, serum-sodium, -potassium, creatinine-clearance, plasma-renin-activity (PRA), plasma-aldosterone (PA) and mean arterial pressure (MAP). After a control period of 4 days the patients received 2 x 6.25 mg/d captopril for 5 days and 4 x 6.25 mg/d for further 5 days. Treatment was followed by a second control period without captopril. PRA increased significantly after 2 days of captopril treatment. 2 x 6.25 mg/d captopril induced a significant increase in sodium excretion and a significant decrease of body weight. MAP decreased slightly but significantly without clinical signs of hypotension. 4 x 6.25 mg/d captopril resulted in a further reduction of body weight and a further enhancement of sodium excretion. Three days after withdrawal of captopril sodium output was significantly reduced again.
CONCLUSION: In cirrhotic patients low-dose captopril seems to be efficient in the treatment of ascites resistant to diuretics without causing major side effects.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2671477     DOI: 10.1007/bf01745350

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  55 in total

1.  Changes in plasma renin activity in cirrhosis: a reappraisal based on studies in 67 patients and "low-renin" cirrhosis.

Authors:  S P Wilkinson; I K Smith; R Williams
Journal:  Hypertension       Date:  1979 Mar-Apr       Impact factor: 10.190

Review 2.  Treatment of cirrhotic ascites.

Authors:  T D Boyer; I S Goldman
Journal:  Adv Intern Med       Date:  1986

3.  Hormones and fluid retention in cirrhosis.

Authors:  E A Espiner; M G Nicholls
Journal:  Lancet       Date:  1982-08-28       Impact factor: 79.321

4.  Physiologic considerations in the medical management of ascites.

Authors:  J T Frakes
Journal:  Arch Intern Med       Date:  1980-05

5.  Sodium regulation of angiotensinogen mRNA expression in rat kidney cortex and medulla.

Authors:  J R Ingelfinger; R E Pratt; K Ellison; V J Dzau
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

6.  Angiotensin II directly stimulates sodium transport in rabbit proximal convoluted tubules.

Authors:  V L Schuster; J P Kokko; H R Jacobson
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

7.  Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites.

Authors:  V Arroyo; J Bosch; M Mauri; F Ribera; F Navarro-López; J Rodés
Journal:  Eur J Clin Invest       Date:  1981-06       Impact factor: 4.686

8.  Effects of captopril on renal function in patients with cirrhosis and ascites.

Authors:  G Daskalopoulos; M Pinzani; N Murray; R Hirschberg; R D Zipser
Journal:  J Hepatol       Date:  1987-06       Impact factor: 25.083

9.  Systemic and renal hemodynamics in oliguric hepatic failure: effect of volume expansion.

Authors:  F E Tristani; J N Cohn
Journal:  J Clin Invest       Date:  1967-12       Impact factor: 14.808

10.  Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis.

Authors:  D G Bichet; V J Van Putten; R W Schrier
Journal:  N Engl J Med       Date:  1982-12-16       Impact factor: 91.245

View more
  1 in total

Review 1.  Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease.

Authors:  J Vlachogiannakos; A K Tang; D Patch; A K Burroughs
Journal:  Gut       Date:  2001-08       Impact factor: 23.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.